Sign inJoin waitlistJoin the waitlist

BR

Bhuvaneswari Ramaswamy

Credentials: · ·

History

Hematology and Medical Oncology
1991–1994
Internal Medicine
1988–1991
Doctor of Medicine
1984–1988

Research

MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1
Journal of Biological Chemistry · 2008 · 639 citations
Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway
Cancer Research · 2012 · Co-first of 7 authors · 169 citations
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative…
Journal of Clinical Oncology · 2018 · 158 citations

Robert Wesolowski
61 papers
Maryam Lustberg
58 papers
Daniel Stover
48 papers
Nicole Williams
41 papers
Sagar Sardesai
40 papers
CS
Charles Shapiro
34 papers
Matthew Cherian
33 papers
Raquel Reinbolt
28 papers · 1 as a fellow
JV
Jeffrey VanDeusen
25 papers
Anne Noonan
20 papers
EM
Ewa Mrozek
18 papers · 1 as a fellow
Rachel Layman
16 papers

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $386.7K · Ohio State University
1997–2025
Addressing Cancer Disparity Through Defining the Molecular Link Between Breast Feeding and Triple Negative Breast Cancer
National Cancer Institute · R01
Contact PI · $1.8M · Ohio State University
2019–2024

Clinical trials

Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer
Principal investigator · Completed · Phase 2
Ohio State University Comprehensive Cancer Center
2015–2020
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2013–2018
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Principal investigator · Terminated · Phase 2
Bhuvaneswari Ramaswamy
2009–2014
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Principal investigator · Completed · Phase 2
Bhuvaneswari Ramaswamy
2007–2017